[{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Juno Therapeutics \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Juno Therapeutics \/ Celgene Corporation"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CC-98633","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Juno Therapeutics \/ Celgene Corporation"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BMS-986393","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Juno Therapeutics \/ Celgene Corporation"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Arlocabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BMS-986453","moa":"BCMA\/GPRC5D","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Celgene Corporation"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CC-95266","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BMS-986393","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Juno Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Juno Therapeutics

Juno Therapeutics
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

02

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

03

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

04

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

05

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

06

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

07

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

08

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

09

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

10

Juno Therapeutics

U.S.A

iPHEX India

Not Confirmed

1
2
3